slides · global inventory
Comparison Table
Framework collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 318
Current window 211-240
Pages 11
Rows per page 30
Framework
211-240 of 318
32
The slide uses a checkmark-based comparison matrix to highlight SPY002's superior profile.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
14
The slide uses a two-part structure: value proposition (Section 1) and competitive benchmarking (Section 2).Benson Hill | Investor Presentation Deck | 28 slides · Benson Hill
Pitch deck Investor relations Beat · SolutionLoop · Why Now1 hit
18
The slide uses a timeline-based comparison structure to highlight shifts in sports rights availability.Disney | Results Presentation Deck | 26 slides · Disney
Conference presentation Investor relations Beat · Visualization1 hit
09
The slide uses a matrix structure to map indications to benchmarks, specific drug regimens, and trial names, with a footer detailing active clinical trial collaboration and supply agreements (CTCSAs).Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations Beat · Challenges in current cancer treatment and unmet needsLoop · Logic Chain1 hit
09
The slide uses a matrix structure to map indications to benchmarks, specific drug regimens, and trial names, with a footer detailing active clinical trial collaboration and supply agreements (CTCSAs).Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
32
The slide uses arrows to visually indicate performance superiority of ERAS-601 over RMC-4550.Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations 1 hit
35
The table uses a color-coded heatmap (green/yellow/red) to indicate performance against criteria.Exscientia | Investor Presentation Deck | 69 slides · Exscientia
Pitch deck Investor relations Beat · Solution (Provide relief)Loop · Golden Circle1 hit
42
The table uses a color-coded system (green/yellow/red) to indicate performance against criteria.Exscientia | Investor Presentation Deck | 75 slides · Exscientia
Pitch deck Investor relations 1 hit
49
The slide uses a traffic-light color coding system to highlight performance against criteria.Exscientia | Investor Presentation Deck | 75 slides · Exscientia
Pitch deck Investor relations 1 hit
42
The slide uses a traffic-light color coding system to highlight the competitive advantage of the company's drug candidate.Exscientia | Investor Presentation Deck | 76 slides · Exscientia
Pitch deck Investor relations 1 hit
17
The table uses a red dashed box to highlight the key clinical data rows (ORR, CR, ICANS, CRS).Immix Biopharma | Investor Presentation Deck | 46 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
21
The slide uses a red dashed box to highlight the core clinical data rows for comparison.Immix Biopharma | Investor Presentation Deck | 49 slides · Immix Biopharma
Pitch deck Investor relations Beat · Evidence & ProofLoop · Cost Of Inaction1 hit
22
The slide uses a comparison table framework to highlight NXC-201's competitive advantage in safety (lower ICANS/CRS) and efficacy (higher ORR/CR).Immix Biopharma | Investor Presentation Deck | 52 slides · Immix Biopharma
Pitch deck Investor relations Beat · Solution1 hit
14
The slide uses a table structure to contrast treatment efficacy and patient outcomes, with a bar chart at the bottom illustrating patient population growth.Immix Biopharma | Investor Presentation Deck | 57 slides · Immix Biopharma
Pitch deck Investor relations Beat · Evidence & ProofLoop · Hypothesis Test1 hit
24
The slide uses a red dashed box to highlight the primary efficacy metrics for comparison.Immix Biopharma | Investor Presentation Deck | 57 slides · Immix Biopharma
Pitch deck Investor relations Beat · Desire1 hit
30
The slide highlights specific safety metrics (CRS and ICANS) for two dosage groups (100x10^6 and 300x10^6 cells).Immix Biopharma | Investor Presentation Deck | 57 slides · Immix Biopharma
Pitch deck Investor relations Beat · Interest1 hit
14
The slide uses a table structure to contrast treatment outcomes and patient growth across three stages of multiple myeloma.Immix Biopharma | Investor Presentation Deck | 58 slides · Immix Biopharma
Pitch deck Investor relations Beat · Interest1 hit
26
The slide uses a comparison table framework to highlight competitive advantage in clinical metrics.Immix Biopharma | Investor Presentation Deck | 58 slides · Immix Biopharma
Pitch deck Investor relations Beat · Interest1 hit
30
The slide highlights specific safety metrics (CRS and ICANS) for two dosage groups (100x10^6 and 300x10^6 cells).Immix Biopharma | Investor Presentation Deck | 58 slides · Immix Biopharma
Pitch deck Investor relations Beat · Desire1 hit
30
The slide uses a red dashed box to highlight the primary efficacy metrics for comparison.Immix Biopharma | Investor Presentation Deck | 60 slides · Immix Biopharma
Pitch deck Investor relations Beat · TractionLoop · Golden Circle1 hit
42
The table compares four different therapies across four criteria categories: Prior lines of therapy, Toxicity recovery, ECOG, and Measurable disease.Immix Biopharma | Investor Presentation Deck | 60 slides · Immix Biopharma
Pitch deck Investor relations Loop · Golden Circle1 hit
30
The slide uses a red dashed box to highlight the primary efficacy metrics for comparison.Immix Biopharma | Investor Presentation Deck | 61 slides · Immix Biopharma
Pitch deck Investor relations Beat · Action1 hit
32
The slide uses a structured comparison table to highlight clinical advantages. It includes a disclaimer about cross-trial comparisons.Immix Biopharma | Investor Presentation Deck | 61 slides · Immix Biopharma
Pitch deck Investor relations Beat · Action1 hit
21
The slide uses a table to contrast treatment efficacy and patient growth across disease stages.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Pitch deck Investor relations Beat · Traction1 hit
07
The slide uses a table to contrast current products with those in the pipeline, with detailed legal footnotes regarding production timelines.Lion Electric | Investor Presentation Deck | 32 slides · Lion Electric
Pitch deck Investor relations Beat · Product1 hit
25
The table compares three treatment regimens across four categories: Expected Efficacy, Safety Profile, Administration, and Trial of Reference.MAIA Biotechnology | Investor Presentation Deck | 39 slides · MAIA Biotechnology
Pitch deck Investor relations 1 hit
17
Matinas BioPharma | Investor Presentation Deck | 28 slidesMatinas BioPharma | Investor Presentation Deck | 28 slides · Matinas BioPharma
Pitch deck Investor relations 1 hit
11
The table uses a green/white color coding to highlight positive attributes of NVL-520 compared to competitors.Nuvalent | Investor Presentation Deck | 52 slides · Nuvalent
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
31
The table uses a green/white color coding to indicate positive vs negative results for specific ALK-related activities.Nuvalent | Investor Presentation Deck | 52 slides · Nuvalent
Pitch deck Investor relations Beat · Traction1 hit
31
The table highlights NVL-655's superior profile in G1202R and GRLM/GRGA/GRLF activity compared to existing therapies.Nuvalent | Investor Presentation Deck | 52 slides · Nuvalent
Pitch deck Investor relations Loop · Jobs To Be Done1 hit